p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and …
R Tang, JY Wang, CW Fan, KC Tsao, HH Chen… - Cancer letters, 2004 - Elsevier
R Tang, JY Wang, CW Fan, KC Tsao, HH Chen, CM Wu, JS Chen, CR Changchien…
Cancer letters, 2004•ElsevierOne hundred and thirty-eight stage II and III colorectal cancer patients were included to
evaluate the prognostic significance of genetic markers (including mutations of the p53, K-
ras genes, and microsatellite instability) on the response to 5-fluorouracil (FU)-based post-
operative adjuvant therapies (PAT). When stratified by PAT and adjusting for other
prognostic variables, presence of p53 mutation was associated with a poor outcome (hazard
ratio (HR)= 3.1, 95% confidence interval (CI), 0.9–11.0) among patients without PAT. Our …
evaluate the prognostic significance of genetic markers (including mutations of the p53, K-
ras genes, and microsatellite instability) on the response to 5-fluorouracil (FU)-based post-
operative adjuvant therapies (PAT). When stratified by PAT and adjusting for other
prognostic variables, presence of p53 mutation was associated with a poor outcome (hazard
ratio (HR)= 3.1, 95% confidence interval (CI), 0.9–11.0) among patients without PAT. Our …
One hundred and thirty-eight stage II and III colorectal cancer patients were included to evaluate the prognostic significance of genetic markers (including mutations of the p53, K-ras genes, and microsatellite instability) on the response to 5-fluorouracil (FU)-based post-operative adjuvant therapies (PAT). When stratified by PAT and adjusting for other prognostic variables, presence of p53 mutation was associated with a poor outcome (hazard ratio (HR)=3.1, 95% confidence interval (CI), 0.9–11.0) among patients without PAT. Our data confirmed that p53 mutation is an independent pre-treatment factor in stage II and III colorectal cancer after curative resection.
Elsevier
